Drug intelligence / Profile preview

human anthrax immunoglobulin

Development stage
Unknown
Lead developer
Guizhou Taibang Biological Products
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Human anthrax immunoglobulin is a plasma-derived polyclonal antibody preparation containing high titers of neutralizing antibodies against the protective antigen (PA) of *Bacillus anthracis*. It is prepared from the pooled plasma of healthy human donors who have been immunized with an anthrax vaccine (such as the Anthrax Vaccine Adsorbed). The drug is designed to provide passive immunity and neutralize anthrax toxins, specifically targeting the PA component to prevent the assembly of lethal toxin and edema toxin, thereby mitigating toxemia associated with inhalational or systemic anthrax infections. In China, a clinical-stage candidate is being co-developed by Guizhou Taibang Biological Products and the Institute of Biotechnology, Academy of Military Medical Sciences, and has completed Phase I clinical evaluation for safety, tolerability, and pharmacodynamics.

Other names
intravenous human anthrax immunoglobulinanthrax immune globulin intravenous (human)anthrax immune globulin静注炭疽人免疫球蛋白
02

Targets

PA (Influenza polymerase acidic protein)

Beyond the preview

Go deeper on human anthrax immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human anthrax immunoglobulin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call